



SOME DRUGS AND HERBAL PRODUCTS

VOLUME 108

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 4–11 June 2013

Lyon, France - 2016

**IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC RISKS
TO HUMANS**

LIST OF ABBREVIATIONS

5-ASA	5-aminosalicylic acid
ACBS	2-amino-4-chloro-1,3-benzenedisulfonamide
AUC	area under the curve
BBN	<i>N</i> -butyl- <i>N</i> -(4-hydroxybutyl)nitrosamine
bw	body weight
CI	confidence interval
CMPF	3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid
CYP	cytochrome P450
DDD	defined daily doses
EPA	Environmental Protection Agency
ELS	evaporative light scattering
ESI-MS	electrospray ionization mass spectroscopy
FDA	United States Food and Drug Administration
GC	gas chromatography
HbA1c	glycated haemoglobin
HCTZ	hydrochlorothiazide
¹ H-NMR	proton nuclear magnetic resonance
HPLC	high-performance liquid chromatography
HPLC/UV	high-performance liquid chromatography/ultraviolet
HPTLC	high-performance thin-layer chromatography
IBD	inflammatory bowel disease
ICD	International Classification of Diseases
KPNC	Kaiser Permanente Northern California
LOQ	limit of quantitation
MRT	mean residence time
MS	mass spectrometry
NADPH	reduced nicotinamide adenine dinucleotide phosphate
NMR	nuclear magnetic resonance
NQO	NAD(P)H quinone oxidoreductase
NTP	National Toxicology Program
OAT	organic anion transporter
OTC	over the counter
PEMA	phenylethyl malonamide

PPAR γ	peroxisome proliferator-activated receptor γ
SMR	standardized morbidity ratio
SSL	solar simulated light
TLC	thin-layer chromatography
TSH	thyroid-stimulating hormone
UGT	UDP glycosyltransferase
USP	United States Pharmacopeia
UV	ultraviolet
v/v	volume for volume
w/w	weight for weight